Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA9CSG)

Drug Name
Beta-methoxyamphetamine Drug Info
Synonyms
4-Methoxyamphetamine; p-Methoxyamphetamine; para-methoxyamphetamine; 1-(4-methoxyphenyl)propan-2-amine; 64-13-1; 1-p-Methoxyphenyl-2-propylamine; 1-p-Methoxyphenyl-2-aminopropane; paramethoxyamphetamine; beta-methoxyamphetamine; 1-(4-Methoxybenzyl)ethylamine; 2-Amino-1-(4'-methoxyphenyl)propane; p-Methoxy-alpha-methylphenethylamine; (+-)-p-Methoxyamphetamine; DEA No 7411; NSC 32757; 50505-80-1; 23239-32-9; DL-p-Methoxy-alpha-methylphenethylamine; (+-)-p-Methoxy-alpha-methylphenethylamine; Para-Methoxyamphetamine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
31721
CAS Number
CAS 64-13-1
TTD Drug ID
DMA9CSG
INTEDE Drug ID
DR0013

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Adrenergic receptor alpha-2A (ADRA2A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lofexidine DM1WXA6 Heroin and opiate withdrawal 6C43 Approved [4]
MOXONIDINE DMGFB0E Alcohol dependence 6C40.2 Approved [5]
Connexyn DMF29Q5 Attention deficit hyperactivity disorder 6A05.Z Approved [6]
Guanfacine DMPN5IH Attention deficit hyperactivity disorder 6A05.Z Phase 4 [7]
A295 DM55GO2 Aggressive cancer 2A00-2F9Z IND submitted [8]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [9]
DSP-1200 DM4WSHG Depression 6A70-6A7Z Phase 1 [10]
MAZAPERTINE DMRHYAU N. A. N. A. Discontinued in Phase 2 [11]
NMI-870 DMU596F Sexual dysfunction HA00-HA01 Discontinued in Phase 2 [12]
SNAP-5089 DMROJEN Heart arrhythmia BC65 Terminated [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Serotonin transporter (SERT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [14]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [15]
Fluoxetine DM3PD2C Bipolar depression Approved [16]
Vortioxetine DM6F1PU Major depressive disorder 6A70.3 Approved [17]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [18]
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [19]
Bupropion DM5PCS7 Depression 6A70-6A7Z Approved [20]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [16]
Nortriptyline DM4KDYJ Depression 6A70-6A7Z Approved [16]
Trazodone DMK1GBJ Depression 6A70-6A7Z Approved [16]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Synaptic vesicle amine transporter (SLC18A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Deutetrabenazine DMUPFLI Huntington disease 8A01.10 Approved [16]
Reserpine DM6VM38 Hypertension BA00-BA04 Approved [21]
Tetrabenazine DMYWQ0O Huntington disease 8A01.10 Approved [21]
Alseroxylon DMB47TQ Hypertension BA00-BA04 Approved [22]
Valbenazine Tosylate DMQSA2V Tardive dyskinesia 8A02.10 Approved [16]
Alkavervir DMB4HFI High blood pressure BA00 Approved [16]
Ingrezza DMVPLNC Tardive dyskinesia 8A02.10 Phase 4 [23]
NBI-98854 DMVO1C0 Movement disorder 8A07-8A0Z Phase 3 [24]
AV 133 DM0EQ9X Alzheimer disease 8A20 Phase 3 [25]
Lobeline DMT3KB4 Substance use disorder 6C4Z Phase 2 [26]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1D (ADRA1D)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxazosin DM9PLRH Benign prostatic hyperplasia GA90 Approved [27]
Armodafinil DMGB035 Malignant glioma 2A00.0 Approved [28]
Alfuzosin DMZVMKF Benign prostatic hyperplasia GA90 Approved [29]
Moxisylyte DMFCLYW Erectile dysfunction HA01.1 Approved [30]
Terazosin DM3JCVS Benign prostatic hyperplasia GA90 Approved [31]
Bunazosin DM4I8O7 Glaucoma/ocular hypertension 9C61 Approved [32]
Trimazosin DM1QLST Congestive heart failure BD10 Approved [33]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [9]
DL-017 DMM8GZT Hypertension BA00-BA04 Phase 1 [34]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [35]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Dopamine transporter (DAT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cocaine DMSOX7I Anaesthesia 9A78.6 Approved [19]
Dasotraline DMLDQFV Attention deficit hyperactivity disorder 6A05.Z Approved [36]
Methylphenidate DM7SJD6 Attention deficit hyperactivity disorder 6A05.Z Approved [37]
Modafinil DMYILBE Malignant glioma 2A00.0 Approved [16]
Phenmetrazine DMXYTN9 Obesity 5B81 Approved [38]
Ioflupane i-123 DMNARJT Parkinson disease 8A00.0 Approved [39]
DEXMETHYLPHENIDATE HYDROCHLORIDE DM8WBAH Attention deficit hyperactivity disorder 6A05.Z Approved [40]
Altropane DMO9WDS Attention deficit hyperactivity disorder 6A05.Z Approved [41]
Amitifadine DMS1X67 Obesity 5B81 Phase 3 [42]
NAV5001 DMRSI1M Dementia 6D80-6D86 Phase 3 [41]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Monoamine oxidase type B (MAO-B)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Selegiline Hydrochloride DM3VR1L Parkinson disease 8A00.0 Approved [43]
Phenelzine DMHIDUE Depression 6A70-6A7Z Approved [44]
Tranylcypromine DMGB5RE Major depressive disorder 6A70.3 Approved [45]
Selegiline DM6034S Major depressive disorder 6A70.3 Approved [46]
Safinamide mesylate DM0J2ZT Parkinson disease 8A00.0 Approved [47]
Rasagiline DM3WKQ4 Parkinson disease 8A00.0 Approved [48]
Sulphadoxine DMZI2UF Malaria 1F40-1F45 Approved [49]
Pargyline DMM0HR1 Hypertension BA00-BA04 Approved [50]
Indeloxazine DMWO3N6 Dementia 6D80-6D86 Approved [39]
Budipine DMODHQI Migraine 8A80 Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Monoamine oxidase type A (MAO-A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Moclobemide DMNZWL7 Depression 6A70-6A7Z Approved [52]
Tranylcypromine DMGB5RE Major depressive disorder 6A70.3 Approved [53]
Clorgyline DMCEUJD Parkinson disease 8A00.0 Approved [54]
Isocarboxazid DMAF1NB Depression 6A70-6A7Z Approved [55]
TRYPTAMINE DMAFPHB N. A. N. A. Phase 3 [56]
Psoralen DMIZJ8M N. A. N. A. Phase 3 [57]
CHF-3381 DMQ2O8V Neuropathic pain 8E43.0 Phase 2 [58]
Ladostigil DMJSY3Q Alzheimer disease 8A20 Phase 2 [59]
CX157 DMS2WB5 Mood disorder 6A60-6E23 Phase 2 [60]
PIPERINE DMYEAB1 Vitiligo ED63.0 Phase 1/2 [61]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adrenergic receptor alpha-1A (ADRA1A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SILODOSIN DMJSBT6 Benign prostatic hyperplasia GA90 Approved [62]
NAFTOPIDIL DMQ8R4E Hypertension BA00-BA04 Approved [62]
Tamsulosin DM5QF9V Benign prostatic hyperplasia GA90 Approved [16]
Xatral DMLHOA0 Benign prostatic hyperplasia GA90 Approved [63]
Dutasteride + tamsulosin DM6P8HU Benign prostatic hyperplasia GA90 Phase 3 [64]
Besipirdine DMLVNTA Cognitive impairment 6D71 Phase 3 [65]
MEDETOMIDINE DMX9Y7V Pain MG30-MG3Z Phase 2 [9]
PMID30124346-Compound-LDT8 DM5MUNG Benign prostatic hyperplasia GA90 Patented [35]
PMID30124346-Compound-LDT66 DMJMTNL Benign prostatic hyperplasia GA90 Patented [35]
TIOSPIRONE DME5QDP N. A. N. A. Discontinued in Phase 3 [66]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [67]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [68]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [69]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [70]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [71]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [72]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [73]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [74]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [75]
Propranolol DM79NTF Angina pectoris BA40 Approved [76]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [77]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [78]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [79]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [80]
Cepharanthine DM9Y5JB N. A. N. A. Approved [81]
Itraconazole DMCR1MV Aspergillosis 1F20 Approved [82]
Clozapine DMFC71L Schizophrenia 6A20 Approved [83]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [84]
Trifluoperazine DMKBYWI Anxiety Approved [85]
Olanzapine DMPFN6Y Bipolar depression Approved [83]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor alpha-1A (ADRA1A) TTNGILX ADA1A_HUMAN Agonist [1]
Adrenergic receptor alpha-1D (ADRA1D) TT34BHT ADA1D_HUMAN Agonist [1]
Adrenergic receptor alpha-2A (ADRA2A) TTWG9A4 ADA2A_HUMAN Agonist [1]
Dopamine transporter (DAT) TTVBI8W SC6A3_HUMAN Antagonist [1]
Monoamine oxidase type A (MAO-A) TT3WG5C AOFA_HUMAN Inhibitor [1]
Monoamine oxidase type B (MAO-B) TTGP7BY AOFB_HUMAN Antagonist [1]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [1]
Synaptic vesicle amine transporter (SLC18A2) TTNZRI3 VMAT2_HUMAN Antagonist [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) Main DME DECB0K3 CP2D6_HUMAN Substrate [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [3]

References

1 Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77.
2 Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol. 1997 Jun 1;53(11):1605-12.
3 P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine. Addict Biol. 2003 Dec;8(4):413-8. doi: 10.1080/13556210310001646475.
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Synthesis and pharmacologic evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: a potent imidazoline1 receptor specific agent. J Med Chem. 1996 Mar 15;39(6):1193-5.
6 alpha2A-adrenergic receptors heterosynaptically regulate glutamatergic transmission in the bed nucleus of the stria terminalis. Neuroscience. 2009 Sep 29;163(1):339-51.
7 Scientific rationale for the use of alpha2A-adrenoceptor agonists in treating neuroinflammatory cognitive disorders. Mol Psychiatry. 2023 Apr 7:1-13.
8 Clinical pipeline report, company report or official report of Klus Pharma
9 A structure-activity relationship study of benzylic modifications of 4-[1-(1-naphthyl)ethyl]-1H-imidazoles on alpha 1- and alpha 2-adrenergic recep... J Med Chem. 1994 Jul 22;37(15):2328-33.
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects. J Med Chem. 1994 Apr 15;37(8):1060-2.
12 Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges. Cardiovasc Hematol Agents Med Chem. 2009 October; 7(4): 260-269.
13 Design and synthesis of novel dihydropyridine alpha-1a antagonists. Bioorg Med Chem Lett. 1999 Oct 4;9(19):2843-8.
14 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
15 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
17 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
18 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
19 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
20 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
21 Dopamine signaling is required for depolarization-induced slow current in cerebellar Purkinje cells. J Neurosci. 2009 Jul 1;29(26):8530-8.
22 Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
23 VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine). Prog Med Chem. 2018;57(1):87-111.
24 NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015 Oct;30(12):1681-7.
25 Brain imaging of vesicular monoamine transporter type 2 in healthy aging subjects by 18F-FP-(+)-DTBZ PET. PLoS One. 2013 Sep 30;8(9):e75952.
26 Design, synthesis and interaction at the vesicular monoamine transporter-2 of lobeline analogs: potential pharmacotherapies for the treatment of psychostimulant abuse. Curr Top Med Chem. 2011;11(9):1103-27.
27 The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43.
28 Mechanisms of modafinil: A review of current research. Neuropsychiatr Dis Treat. 2007 June; 3(3): 349-364.
29 Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
30 Pharmacokinetics of moxisylyte in healthy volunteers after intracavernous injection of increasing doses. Eur J Clin Pharmacol. 1996;49(5):411-5.
31 Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component. Prostate Cancer Prostatic Dis. 2002;5(2):88-95.
32 Bunazosin, a selective alpha1-adrenoceptor antagonist, as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev. 2005 Spring;23(1):43-56.
33 The hypotensive effect of trimazosin is not caused solely by alpha 1-adrenoceptor blockade. J Cardiovasc Pharmacol. 1984 Jan-Feb;6(1):142-50.
34 Antihypertensive action and blockade of alpha1-adrenoceptors by DL-017, a quinazoline derivative. J Cardiovasc Pharmacol. 2001 Dec;38(6):893-9.
35 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
36 Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
37 Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005 Jun 1;57(11):1410-5.
38 Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
39 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
40 Synthesis and pharmacology of site-specific cocaine abuse treatment agents: restricted rotation analogues of methylphenidate. J Med Chem. 2007 May 31;50(11):2718-31.
41 Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun;29(2):128-41.
42 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 927).
43 Emerging drugs for Parkinson's disease. Expert Opin Emerg Drugs. 2006 Sep;11(3):403-17.
44 Limitation of adipose tissue enlargement in rats chronically treated with semicarbazide-sensitive amine oxidase and monoamine oxidase inhibitors. Pharmacol Res. 2008 Jun;57(6):426-34.
45 Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73.
46 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2490).
47 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
48 Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res. 2009 Aug;16(2):148-59.
49 Novel monoamine oxidase inhibitors, 3-(2-aminoethoxy)-1,2-benzisoxazole derivatives, and their differential reversibility. Jpn J Pharmacol. 2002 Feb;88(2):174-82.
50 Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8.
51 Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm Suppl. 1999;56:83-105.
52 Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Hum Psychopharmacol. 2002 Dec;17(8):401-5.
53 Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice. Int J Neuropsychopharmacol. 2009 Mar 11:1-11.
54 Further investigation into the mechanism of tachykinin NK(2) receptor-triggered serotonin release from guinea-pig proximal colon. J Pharmacol Sci. 2009 May;110(1):122-6.
55 MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
56 Binding of beta-carbolines at imidazoline I2 receptors: a structure-affinity investigation. Bioorg Med Chem Lett. 2004 Feb 23;14(4):999-1002.
57 Inhibition of rat brain monoamine oxidase activities by psoralen and isopsoralen: implications for the treatment of affective disorders. Pharmacol Toxicol. 2001 Feb;88(2):75-80.
58 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
59 Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimer's disease treatment. Curr Drug Targets. 2012 Apr;13(4):483-94.
60 Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology. 2010 Feb;35(3):623-31.
61 Proposed structural basis of interaction of piperine and related compounds with monoamine oxidases. Bioorg Med Chem Lett. 2010 Jan 15;20(2):537-40.
62 Pharmacophore identification of alpha(1A)-adrenoceptor antagonists. Bioorg Med Chem Lett. 2005 Feb 1;15(3):657-64.
63 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
64 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
65 Alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46.
66 3-Benzisothiazolylpiperazine derivatives as potential atypical antipsychotic agents. J Med Chem. 1996 Jan 5;39(1):143-8.
67 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
68 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
69 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
70 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
71 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
72 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
73 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
74 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
75 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
76 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
77 Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
78 Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
79 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
80 Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
81 Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
82 Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
83 Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
84 Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
85 Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.